Xortx Therapeutics Inc (XRTX) Stock Price, Quote & News

Company Profile

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus;...

Industry: Biotechnology

Sector: Healthcare

Phone: 403-455-7727

Website: www.xortx.com

Address:

3710 - 33rd Street NW, Calgary, Canada

Biotech80 Jun. 29 at 8:23 AM

$XRTX

0 · Reply

Biotech80 Jun. 26 at 12:31 PM

$XRTX let’s go going to be a great few days 🚀🚀🤑💎💎💎💎💎

0 · Reply

LookaLike Jun. 18 at 6:25 PM

$XRTX a turtle is moving faster than this

0 · Reply

honestrick Jun. 16 at 1:14 AM

$XRTX Voluntarily delisting from the tsx venture .Good riddance . Shares will convert over to the Nasdaq .. Things will start to move now ...Up I hope .

0 · Reply

DARKP00L Jun. 15 at 12:04 PM

$XRTX 07:49 on Jun. 15 2026 XORTX Therapeutics Appoints Mika Grasso Co-CEO #tradeideas

0 · Reply

focafoca99 Jun. 15 at 11:50 AM

$XRTX appointed Mika Grasso as co-CEO to drive its gout and kidney program strategy.

0 · Reply

LookaLike Jun. 4 at 7:32 AM

$XRTX new presentation out, IND and NDA filing postponed again. NDA postponed into H2 2027. It shouldve been a short timeline to NDA review but now it turns out to be a long one.

0 · Reply

LookaLike May. 19 at 5:52 PM

$XRTX offering closed, cash position is higher than marketcap now

0 · Reply

lindastocks958 May. 18 at 1:23 AM

$XRTX

0 · Reply

honestrick May. 15 at 12:21 PM

$XRTX Offering on May 14 and a close on May 15 is a very good sign that investors have been looking at and talking with $XRTX for a few months . The 3 new directors were elected for a reason .

1 · Reply

XRTX Welcomes Mika Grasso as New Co-CEO for Finance and Public Markets

2026-06-15T11:27:57.000Z - 15 days ago

Xortx Therapeutics announces Mika Grasso as co-CEO

Mon, 15 Jun 2026 07:00:00 -0400 - 15 days ago

XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO

Fri, 12 Jun 2026 17:00:00 -0400 - 17 days ago

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

Tue, 19 May 2026 07:00:00 -0400 - 6 weeks ago

XORTX Announces Closing of US$5 Million Public Offering

Mon, 18 May 2026 11:20:00 -0400 - 6 weeks ago

E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering

2026-05-14T20:33:59.000Z - 6 weeks ago

XRTX Announces Public Offering of Shares

2026-05-14T19:08:33.000Z - 6 weeks ago

Xortx Therapeutics 2.66M share Spot Secondary priced at $1.88

XRTX

Thu, 14 May 2026 07:00:00 -0400 - 6 weeks ago

XORTX Announces US$5 Million Public Offering

2026-04-21T14:45:55.000Z - 2 months ago

XORTX Regains Nasdaq Compliance, Stock Up

2026-04-21T14:32:51.000Z - 2 months ago

XRTX Achieves Nasdaq Compliance Following Share Price Recovery

2026-04-21T12:45:47.000Z - 2 months ago

Xortx Therapeutics meets Nasdaq continued listing requirements

2026-04-14T06:56:22.000Z - 2 months ago

XORTX Closes Acquisition Of Kidney Anti-fibrotic Asset From Vectus; Stock Down

2026-04-01T17:05:46.000Z - 3 months ago

Xortx Therapeutics to effect 5-for-1 share consolidation on April 6

Wed, 01 Apr 2026 13:00:00 -0400 - 3 months ago

XORTX Confirms Effective Date of Share Consolidation

Thu, 26 Mar 2026 18:00:00 -0400 - 3 months ago

XORTX Announces Results of Annual and Special Meeting of Shareholders

Thu, 26 Mar 2026 16:32:00 -0400 - 3 months ago

XORTX Announces Change of Effective Date of Share Consolidation

Wed, 25 Mar 2026 18:15:00 -0400 - 3 months ago

XORTX Announces Share Consolidation

2026-03-18T11:26:41.000Z - 3 months ago

Xortx Therapeutics announces three new director nominees

2026-03-13T11:11:51.000Z - 3 months ago

Xortx reports proxy firms recommend shareholders vote ‘FOR’ share consolidation

Fri, 13 Mar 2026 07:00:00 -0400 - 3 months ago

XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation

2026-03-05T12:33:09.000Z - 4 months ago

XORTX Therapeutics (XRTX) Announces Key Shareholder Meeting Agenda

2026-03-05T12:18:22.000Z - 4 months ago

Xortx Therapeutics announces filing of meeting documents

2026-02-05T09:34:03.000Z - 5 months ago

Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

2026-02-05T07:10:06.000Z - 5 months ago

XORTX Extends Closing Of Renal Anti-Fibrotic Therapeutic Program Acquisition; Stock Soars

2025-10-21T12:20:49.000Z - 9 months ago

Xortx Therapeutics prices 1.75M shares at 63c in registered direct offering

Tue, 21 Oct 2025 08:00:00 -0400 - 9 months ago

XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

2025-10-21T06:55:29.000Z - 9 months ago

XORTX Therapeutics (XRTX) Secures Nasdaq Extension to Meet Bid Price Rule

Mon, 20 Oct 2025 20:34:00 -0400 - 9 months ago

XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

Mon, 20 Oct 2025 18:45:00 -0400 - 9 months ago

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

2025-10-17T13:42:59.000Z - 9 months ago

Why Is XORTX Therapeutics Stock (XRTX) Up 20% Today?

2025-10-17T12:35:39.000Z - 9 months ago

XORTX (XRTX) Acquires Renal Therapeutic Program from Vectus

2025-10-17T11:05:16.000Z - 9 months ago

Xortx to acquire Renal Anti-Fibrotic Therapeutic Program from Vectus for $3M

Fri, 17 Oct 2025 07:00:00 -0400 - 9 months ago

XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

2025-09-25T20:25:29.000Z - 9 months ago

Xortx Therapeutics files to sell 4.76M common shares

2025-09-09T13:01:00.000Z - 10 months ago

XORTX Therapeutics goes ‘toe to toe’ with gout by accelerating its lead drug program targeting this complex disease

2025-09-03T11:11:43.000Z - 10 months ago

Xortx Therapeutics initiates IND preparation for XORLO in gout program

Wed, 03 Sep 2025 07:00:00 -0400 - 10 months ago

XORTX Initiates IND Preparation for XORLO™ in Gout Program

Fri, 08 Aug 2025 19:54:00 -0400 - 11 months ago

XORTX Completes USD $114,500 Private Placement

2025-08-07T12:02:26.000Z - 11 months ago

Xortx Therapeutics announces planned goals for 2026

2025-07-31T11:20:31.000Z - 11 months ago

Xortx Therapeutics prices 156,849 units at 73c in private placement

Tue, 22 Jul 2025 19:59:00 -0400 - 1 year ago

XORTX Completes Non-Brokered Private Placement of Units

Thu, 26 Jun 2025 07:00:00 -0400 - 1 year ago

XORTX Announces USD $925,000 Private Placement

2025-05-19T11:15:25.000Z - 1 year ago

Xortx Therapeutics prices 3.41M units at 88c in private placement

Mon, 19 May 2025 07:00:00 -0400 - 1 year ago

XORTX Announces USD $3 Million Offering

2025-04-30T11:14:55.000Z - 1 year ago

Xortx Therapeutics provides update on FDA Type B meeting request

2025-04-28T11:11:02.000Z - 1 year ago

Xortx Therapeutics announces grant of European patent

2025-04-18T07:55:25.000Z - 1 year ago

XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge

2025-04-18T00:00:24.000Z - 1 year ago

Xortx Therapeutics discloses Nasdaq notification regarding minimum bid price

Thu, 17 Apr 2025 19:45:00 -0400 - 1 year ago

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jan 17, 2025, 5:00 PM EST - 1 year ago

XORTX Announces Change of Auditor

Dec 12, 2024, 9:17 AM EST - 1 year ago

XORTX Announces Presentation at the Rare and Genetic Disease Summit

Oct 18, 2024, 4:00 PM EDT - 1 year ago

XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

Oct 9, 2024, 5:00 AM EDT - 1 year ago

XORTX Initiates Precision Medicine Program

Sep 13, 2024, 7:00 AM EDT - 1 year ago

XORTX Announces Results of Annual and Special Meeting of Shareholders

Sep 12, 2024, 5:30 PM EDT - 1 year ago

XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A

Sep 6, 2024, 5:30 PM EDT - 1 year ago

XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders

Sep 3, 2024, 12:30 PM EDT - 1 year ago

Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

Aug 23, 2024, 7:00 AM EDT - 2 years ago

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

Aug 20, 2024, 7:00 AM EDT - 2 years ago

XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024

May 17, 2024, 7:00 AM EDT - 2 years ago

XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO

Apr 30, 2024, 1:54 PM EDT - 2 years ago

XORTX Reprices Warrants Issued in Connection with Previous Private Placements

Apr 22, 2024, 7:00 AM EDT - 2 years ago

XORTX Announces Publication of Key Research in ADPKD

Apr 8, 2024, 7:30 AM EDT - 2 years ago

XORTX Welcomes New Member to the Board of Directors

Mar 27, 2024, 5:00 AM EDT - 2 years ago

XORTX Announces New Clinical Advisory Board Member

Mar 19, 2024, 5:00 AM EDT - 2 years ago

XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial

Mar 4, 2024, 7:00 AM EST - 2 years ago

XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units

Feb 1, 2024, 8:46 PM EST - 2 years ago

XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units

Jan 15, 2024, 7:00 AM EST - 2 years ago

XORTX Announces $2 Million Public Offering

Jan 3, 2024, 7:00 AM EST - 2 years ago

XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease

Nov 30, 2023, 7:30 AM EST - 2 years ago

XORTX Announces US ATM Offering

Nov 29, 2023, 7:00 AM EST - 2 years ago

XORTX Meets Nasdaq Continued Listing Requirements

Nov 10, 2023, 7:00 AM EST - 2 years ago

XORTX Clarifies Timing for Share Consolidation

Oct 27, 2023, 5:30 PM EDT - 2 years ago

XORTX Announces Results of Special Meeting of Shareholders

Oct 25, 2023, 5:00 PM EDT - 2 years ago

XORTX Announces Date for Rescheduled Special Meeting of Shareholders

Oct 25, 2023, 7:00 AM EDT - 2 years ago

XORTX Announces Rescheduling of Special Meeting of Shareholders

Oct 12, 2023, 7:00 AM EDT - 2 years ago

XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution

Oct 4, 2023, 7:00 AM EDT - 2 years ago

XORTX Calls Special Meeting of Shareholders

Aug 29, 2023, 7:00 AM EDT - 3 years ago

XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease

Aug 4, 2023, 5:00 PM EDT - 3 years ago

XORTX Appoints Chief Financial Officer

Biotech80 Jun. 29 at 8:23 AM

$XRTX

0 · Reply

Biotech80 Jun. 26 at 12:31 PM

$XRTX let’s go going to be a great few days 🚀🚀🤑💎💎💎💎💎

0 · Reply

LookaLike Jun. 18 at 6:25 PM

$XRTX a turtle is moving faster than this

0 · Reply

honestrick Jun. 16 at 1:14 AM

$XRTX Voluntarily delisting from the tsx venture .Good riddance . Shares will convert over to the Nasdaq .. Things will start to move now ...Up I hope .

0 · Reply

DARKP00L Jun. 15 at 12:04 PM

$XRTX 07:49 on Jun. 15 2026 XORTX Therapeutics Appoints Mika Grasso Co-CEO #tradeideas

0 · Reply

focafoca99 Jun. 15 at 11:50 AM

$XRTX appointed Mika Grasso as co-CEO to drive its gout and kidney program strategy.

0 · Reply

LookaLike Jun. 4 at 7:32 AM

$XRTX new presentation out, IND and NDA filing postponed again. NDA postponed into H2 2027. It shouldve been a short timeline to NDA review but now it turns out to be a long one.

0 · Reply

LookaLike May. 19 at 5:52 PM

$XRTX offering closed, cash position is higher than marketcap now

0 · Reply

lindastocks958 May. 18 at 1:23 AM

$XRTX

0 · Reply

honestrick May. 15 at 12:21 PM

$XRTX Offering on May 14 and a close on May 15 is a very good sign that investors have been looking at and talking with $XRTX for a few months . The 3 new directors were elected for a reason .

1 · Reply

OpenOutcrier May. 14 at 12:59 PM

$XRTX (-12.8% pre) Kidney drug developer XORTX prices US$5M Nasdaq share sale https://ooc.bz/l/102321

0 · Reply

honestrick May. 12 at 5:10 PM

$XRTX Let er RIP ....

0 · Reply

LookaLike May. 6 at 6:43 PM

$XRTX waiting for news

0 · Reply

SuperGreenToday May. 5 at 6:31 PM

$XRTX

0 · Reply

honestrick May. 4 at 2:17 PM

$BB All the heavy lifting has been done on these stocks $NXE $BLDP $XRTX $SEGG Over the past few years ... Its time to reap the benefits .

0 · Reply

LookaLike Apr. 30 at 6:40 PM

$XRTX hopefully next $DRUG

0 · Reply

LookaLike Apr. 24 at 4:39 PM

$XRTX yes picking up

0 · Reply

honestrick Apr. 24 at 2:38 PM

$XRTX They may need $$$$ but with the pipe line they have and the 3 new directors who ALL have connections to investors $$$ should hold the price .It will bounce around but should start to climb . $DRUG

0 · Reply

honestrick Apr. 24 at 2:28 PM

$XRTX

0 · Reply

LookaLike Apr. 23 at 6:27 PM

$XRTX the presplit price is 0,54, this is still very low. This should trade at least at 10 Million marketcap with the acquisition they finalized. This would translate into 7 $ per share considering 1.5 million shares outstanding

0 · Reply

LookaLike Apr. 22 at 7:03 PM

$XRTX from red to green, nice performance

0 · Reply

TheBeautifulGopher Apr. 22 at 1:01 PM

$XRTX hello XRTX board, you had a nice pop for compliance news. $HKIT did their reverse split the same time as you and we’re waiting for ours. Should be getting it tomorrow 😎

0 · Reply

Market Cap	3.79M
Revenue (ttm)	0.00
Net Income (ttm)	-2.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	13,222
Avg Vol	1,517,060
Day's Range	N/A - N/A
Shares Out	1.73M
Stochastic %K	72%
Beta	0.74
Analysts	Strong Buy
Price Target	$70.00